Biotechnology - Licensing, Nephrology and Hepatology

Filter

Popular Filters

Cytori licenses Asia-Pacific cardiovascular, renal and diabetes markets to Lorem Vascular for up to $531 million

05-11-2013

San Diego, USA-based Cytori Therapeutics and China-headquartered Lorem Vascular have entered a partnership…

Asia-PacificBiotechnologyCardio-vascularCytori TherapeuticsDiabetesLicensingLorem VascularMergers & AcquisitionsNephrology and Hepatology

Evolva to license EV-077 to Serodus

07-10-2013

Switzerland-based Evolva Holding and Norwegian biopharma company Serodus have signed a binding term…

BiotechnologyDiabetesEV-077EvolvaLicensingNephrology and HepatologyPharmaceuticalSerodus

AstraZeneca to fork out $815 million for rights to anemia drug candidate

31-07-2013

In yet another move to boost its R&D pipeline, Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered…

Asia-PacificASP1517Astellas PharmaAstraZenecaBiotechnologyFG-4592FibroGenLicensingNephrology and HepatologyNorth AmericaPharmaceuticalResearch

Amgen and KPCB to create Atara Biotherapeutics; Banner Pharmacaps changes hands

29-10-2012

The world's largest biotech firm Amgen (Nasdaq: AMGN) and venture capital group Kleiner Perkins Caufield…

AmgenAtara BiotherapeuticsBanner PharmacapsBiotechnologyLicensingMergers & AcquisitionsNephrology and HepatologyOncologyPatheonPharmaceuticalProduction

Nektar sells Cimzia and Mircera royalty rights for $124 million

01-03-2012

US biotech firm Nektar Therapeutics (Nasdaq: NKTR) has agreed to sell to Royalty Pharma its royalties…

Anti-Arthritics/RheumaticsBiotechnologyLicensingNephrology and Hepatology

Ligand licenses DARA Program to Retrophin

21-02-2012

USA-based Ligand Pharmaceuticals (Nasdaq: LGND) has entered into an agreement in which it has licensed…

BiotechnologyDARALicensingLigand PharmaceuticalsNephrology and HepatologyPharmaceuticalRare diseasesResearchRetrophin

Agenus out-licenses Russian rights to cancer vaccine

20-12-2011

US biotech firm Agenus (Nasdaq: AGEN), known as Antigenics until January of this year, has entered into…

AgenusAntigenicsBiotechnologyChemRar Hi-TechEuropeLicensingNephrology and HepatologyNewVacOncologyOncophagePharmaceuticalResearch

Back to top